NCT07635524
A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.
Not Yet Recruiting
PHASE2Ages 18+InterventionalDiagnosticHoag Memorial Hospital PresbyterianInvestigator-initiated
~34 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Cu-NU101
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity of imaging with 61Cu- NU101,
Measured over 4 hours post-administration
Conditions
Where it's being run
2 sites across 2 statesCalifornia1
Missouri1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Sensitivity of imaging with 61Cu- NU101,4 hours post-administration
Demonstrate the sensitivity of imaging with 61Cu- NU101, as compared to a currently standard of care PSMA-targeted imaging agent, 18F-piflufolastat.